UNSPSC 51433401: Diproteverine

This classification denotes a calcium channel blocker with the molecular formula C26H35NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8A5OIA91GT, chemically known as 1-(3,4-diethoxybenzyl)-3,4-dihydro-6,7-diisopropoxyisoquinoline but generally known as diproteverine, which bears US NIH Compound Identifier 50463. European Medicines Agency schedules Diproteverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07227MIG.

UNSPSC 51433401 Diproteverine is a Commodity code that covers advanced life support and emergency pharmaceutical medications supplied to fire rescue, emergency medical services, and state pharmacy benefit programs. The code sees activity from municipal fire departments, state health agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Recent solicitations show state and local buyers purchasing specific emergency medications—epinephrine, labetalol, adenosine, and diltiazem formulations—either as direct line-item procurements or as part of broader generic pharmaceutical aggregation agreements. The City of Tampa's fire rescue department and the Texas Health and Human Services Commission represent the kinds of issuing bodies pursuing work under this code, supported by cooperative purchasing mechanisms such as the Minnesota Multistate Cooperative Purchasing Alliance that consolidate orders across state and local member agencies.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) for Advanced Life Support Medications on April 24, 2026, with a due date of April 8, 2026, seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials at an estimated contract value of $40,000.00 with a one-year term and options to renew for two additional years. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration issued an RFP through the MMCAP cooperative purchasing vehicle in January 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026. Tampa's solicitation carries a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount not to exceed $10,000.